Recent data suggests that retatrutide, a innovative medication, could represent a significant advance in size management. This therapy combines the effects of a GLP-1 agonist and a GIP analog, potentially offering a enhanced outcome than available therapies . Clinical trials have shown positive findings , including considerable decreases in body an